Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Psoriasis
  • Systemic Inflammation
Type
Observational
Design
Observational Model: Case-ControlTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 70 years
Gender
Only males

Description

We have previously shown that fasting, and the caloric restriction mimetic nicotinamide riboside (NR) confer anti-inflammatory effects on a broad array of circulating innate and adaptive immune cells. Three major effects include fasting-mediated blunting of the NLRP3 inflammasome and of CD4+Th17 res...

We have previously shown that fasting, and the caloric restriction mimetic nicotinamide riboside (NR) confer anti-inflammatory effects on a broad array of circulating innate and adaptive immune cells. Three major effects include fasting-mediated blunting of the NLRP3 inflammasome and of CD4+Th17 responsiveness, and of NR-induced downregulation of monocytic type 1 interferon signaling. In parallel, dietary interventions including intermittent fasting (IF-alternate day eating) and time-restricted feeding (TRF-for e.g. eating during the first 6 hours after waking each day) reduce inflammatory and cardiometabolic risk factors. Animal studies suggest that pharmacologic mimics of dietary restriction are inferior to dietary manipulations themselves. This discrepancy is postulated to be due to wide array of biological responses evoked by the 'low levels of stress' (hormesis) evoked by IF or TRF compared to the targeting of distinct biological pathways. Hence to advance our understanding on the role of these dietary interventions on immune modulation in health and disease, a pilot study is being planned to test the effect of TRF in subjects with mild to moderate psoriasis compared to a matched healthy control population. For this pilot study we elected to employ TRF over IF, as this will enable repetitive hormesis periods in a relative short time span to compare TRF immunological signatures to conventional dietary intervals. This initial study will be domiciled in the Clinical Center Metabolic Unit in collaboration with NIDDK Investigators, to ensure complete adherence to the TRF in this initial proof of concept study. Psoriasis has been selected as the disease comparator to the control group in this initial study, as this is a chronic inflammatory skin disease that effects cardiometabolic risk and is linked to both the NLRP3 inflammasome and Th17 inflammation.

Tracking Information

NCT #
NCT04728165
Collaborators
Not Provided
Investigators
Principal Investigator: Michael N Sack, M.D. National Heart, Lung, and Blood Institute (NHLBI)